Fortrea Collaborates With Omico Over Biomarker-Driven Oncology Research

05:49 PM EDT, 10/22/2026 (MT Newswires) -- Fortrea (FTRE) entered a collaboration with Australia-based Omico to connect cancer patients to biomarker-matched clinical trials in a bid to advance precision oncology research in Australia, the companies said in a late Thursday statement. Omico will provide Fortrea's clients access to patient population insights, including genomic profiling, trial-matching capabilities, and patient referral pathways in Australia, according to a statement. The initiative is expected to improve study planning, site selection, and patient recruitment, according to the companies.